Immunotech Biopharm Ltd
永泰生物製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6978)

CHANGE OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board announces that with effect from 16 October 2025:

1. Mr Cao Ran has been appointed as a non-executive Director and a member of the Audit Committee; and

2. Ms Yu Xiaohui has resigned as a non-executive Director and a member of the Audit Committee.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The board (the "**Board**") of directors (the "**Director(s)**") of Immunotech Biopharm Ltd (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that with effect from 16 October 2025, Mr Cao Ran (曹冉) ("**Mr Cao**") has been appointed as a non-executive Director and a member of the audit committee of the Company (the "**Audit Committee**").

The biography of Mr Cao is set out below:

Mr Cao Ran, aged 43, obtained a Bachelor of Engineering degree in Pharmaceutical Engineering from Beijing Union University in the PRC in 2005.

Mr Cao has extensive experience in operation and pharmaceutical production management. Since 2005, he has served successively at China Resources Double-Crane Pharmaceutical Co., Ltd., a listed company on the Shanghai Stock Exchange with a stock code of 600062, and China Resources Pharmaceutical Holdings Co., Ltd., engaging in production management, operational management, post-investment management. He currently holds the position of Deputy General Manager of the Operations Management Department of China Resources Pharmaceutical Holdings Co., Ltd.

The term for the appointment of Mr Cao as a non-executive Director is three years and his appointment is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr Cao is not entitled to any Director's fee under his appointment letter.

Pursuant to the articles of association of the Company, Mr Cao shall hold office only until the first annual general meeting of the Company after his appointment where he shall be eligible for re-election. He shall be subject to retirement by rotation thereafter and shall then be eligible for re-election.

Save as disclosed above, as at the date of this announcement, Mr Cao confirmed that (i) he does not hold any position in the Company or any of its subsidiaries nor have any relationship with any Directors, senior management or substantial or controlling shareholders (having the meaning ascribed to it in the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**")) of the Company; (ii) he has not held other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) he does not have other major appointments and professional qualifications; (iv) he does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules or other matters that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") in connection with his appointment as a non-executive Director.

The Board would like to express its warmest welcome to Mr Cao for joining the Board.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board further announces that Ms Yu Xiaohui (于曉輝) ("**Ms Yu**") has resigned from her positions as a non-executive Director and a member of the Audit Committee with effect from 16 October 2025, due to her other job arrangement. Ms Yu has confirmed that she has no disagreement with the Board and there are no other matters with respect to her resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Ms Yu for her valuable contribution to the Company during her tenure of service.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 16 October 2025

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.